C

Merck & Co., Inc. MRK

$143.93 -$0.78-0.54% NYSE
Recommendation
Dividend Power Score
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
52-Week Range
P/E (TTM)
EPS (TTM)
Access our Premium Ratings
Get Access

Rating

Reward
Risk

Rating Factors

Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index

Company Overview

Merck & Co., Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing prescription medicines, vaccines, biologic therapies, and animal health products. The company operates primarily in the pharmaceutical and animal health industries, with research capabilities spanning oncology, infectious diseases, vaccines, cardiometabolic disorders, immunology, and veterinary medicine. Merck generates the majority of its revenue from branded pharmaceutical products, with oncology therapy Keytruda and the Gardasil vaccine franchise serving as major revenue drivers according to recent SEC filings and company annual reports.

The company’s principal business lines include its Pharmaceutical segment and Animal Health segment. Merck serves hospitals, physicians, government agencies, wholesalers, distributors, and veterinary providers across developed and emerging markets. A significant strategic advantage has been its leadership in immuno-oncology through Keytruda, which has become one of the highest-selling prescription drugs globally. Merck traces its U.S. origins to 1891, when it was established as the American subsidiary of the German company Merck KGaA. The company evolved into an independent U.S.-based corporation after World War I and has since expanded through internal research and acquisitions, including the merger with Schering-Plough in 2009.

Data compiled by narrative technology. May contain errors.
Sector

Income Statement

Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)

Balance Sheet

Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)

Cash Flow

Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)

Filings

Filing Date
Friday, August 7, 2026
Period Date
Tuesday, June 30, 2026
Next Filing
Week of Nov 2 and 6 (est)

Price History

Loading...
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
52-week Low
52-week High

Valuation

Market Cap
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)

Dividends and Shares

Shares Outstanding
Dividend Per Share (Most Recent)
Dividend Per Share (TTM)

Corporate Info

Phone Number
908 740 4000
Address
126 East Lincoln Avenue
Rahway, NJ 07065
Country
Year Founded

Headlines